Generic Name and Formulations:
Liothyronine (as sodium) 10mcg/mL; soln for IV inj.
Par Pharmaceutical, Inc.
Indications for TRIOSTAT:
Give with glucocorticoids. Allow 4–12 hours between doses. Initially 25–50mcg. Cardiovascular disease: initially 10–20mcg. Usual range: 65–100mcg daily. Change to oral therapy as soon as possible: start tabs at low dose and increase gradually; discontinue IV gradually.
Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis. Artificial rewarming.
Not for treatment of obesity for weight loss.
Ineffective for weight reduction in euthyroid patients. Not for treatment of infertility. Cardiovascular disease, angina, elderly: initiate therapy at 10–20micrograms. Severe and prolonged hypothyroidism. Fluid therapy. Adrenocortical insufficiency. Pregnancy (Cat.A). Nursing mothers.
Potentiates digitalis toxicity, tricyclic antidepressants, sympathomimetics (eg, anorectics). May increase risk of coronary insufficiency with vasopressors. Monitor oral anticoagulants, hypoglycemics. Estrogens affect thyroid function tests. May be potentiated by tricyclic antidepressants. Hypertension, tachycardia with ketamine.
Arrhythmia, tachycardia, cardiopulmonary arrest, hypotension, MI, angina, CHF, hypertension, twitching.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline